Amonafide clinical trials
Includes 1 study of Amonafide dihydrochloride.
How each study uses amonafide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2003 (1)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2007 | 1 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Antisoma Research (2) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses amonafide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Amonafide in Treating Women With Metastatic Breast Cancer That Has Progressed After Previous ChemotherapyCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00074100Written as amonafide dihydrochloride
- A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)Status unknownPhase 2Antisoma ResearchNCT01066494Written as Amonafide + cytarabine
- Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE StudyStatus unknownPhase 3Antisoma ResearchNCT00715637Written as Amonafide and Cytarabine
Codes
What other systems call amonafide · ClinicalTrials.gg INT003070
- MeSH (NLM) C037020amonafideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1Q8D39N37LAMONAFIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1440270Confirmed FDA, Wikidata
- Wikidata Q4747531amonafideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71628AmonafideOne source FDA
- DrugBank DB05022One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C037020 | amonafide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1Q8D39N37L | AMONAFIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1440270 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4747531 | amonafide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71628 | Amonafide | One source FDA |
| DrugBank | DB05022 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.